Payment overview · 2025
General Payments
$2,365.77
101 reported records · 28 companies
Healthcare provider profile · identity verified
Mazen Khusayem, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLAYTON, NC · NPI 1285604934
Verified facts
What the public records show
CMS Open Payments records show Mazen Khusayem, MD received $2,365.77 in general payments during 2025 across 101 reported records.
Novo Nordisk Inc accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $530.69 | 22.4% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $340.97 | 14.4% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $291.81 | 12.3% | 14 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $167.92 | 7.1% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $157.67 | 6.7% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $113.60 | 4.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $107.47 | 4.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $86.99 | 3.7% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$53.25 | 2.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $47.65 | 2.0% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $46.32 | 2.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $44.40 | 1.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $41.52 | 1.8% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $40.76 | 1.7% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $37.50 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.24 | 1.4% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.21 | 1.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.43 | 1.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.91 | 1.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.11 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.92 | 0.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.59 | 0.7% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $15.57 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.76 | 0.6% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.50 | 0.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.28 | 0.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $14.12 | 0.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.61 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,365.77 | 101 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $358.16 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $253.16 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $172.53 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $167.92 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $122.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $107.47 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $105.00 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $103.16 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $97.66 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $95.16 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $83.86 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $81.48 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $75.08 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $63.95 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.47 | 4 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $53.25 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $50.28 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $46.32 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $45.27 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.40 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $41.52 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $40.76 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $38.65 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $37.50 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.28 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.21 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 93 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 181 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 142 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
142 | 26 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
181 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 905 | 258 |
| Amlodipine Besylate | Amlodipine Besylate | 665 | 186 |
| Levothyroxine Sodium | Levothyroxine Sodium | 626 | 160 |
| Gabapentin | Gabapentin | 490 | 147 |
| Metformin Hcl | Metformin Hcl | 489 | 145 |
| Pantoprazole Sodium | Pantoprazole Sodium | 407 | 119 |
| Carvedilol | Carvedilol | 376 | 109 |
| Tramadol Hcl | Tramadol Hcl | 276 | 74 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 276 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 76 |
| Losartan Potassium | Losartan Potassium | 271 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 234 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 230 | 55 |
| Lisinopril | Lisinopril | 222 | 65 |
| Alprazolam | Alprazolam | 218 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 215 | 77 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 199 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 196 | 62 |
| Omeprazole | Omeprazole | 194 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 44 |
| Potassium Chloride | Potassium Chloride | 189 | 40 |
| Ozempic | Semaglutide | 181 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 165 | 51 |
| Furosemide | Furosemide | 164 | 45 |
| Lorazepam | Lorazepam | 164 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 162 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 158 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 152 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 23 |
| Simvastatin | Simvastatin | 145 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 142 | 26 |
| Trazodone Hcl | Trazodone Hcl | 139 | 31 |
| Methylprednisolone | Methylprednisolone | 135 | 104 |
| Torsemide | Torsemide | 125 | 33 |
| Mirtazapine | Mirtazapine | 124 | 36 |
| Clonazepam | Clonazepam | 122 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 35 |
| Famotidine | Famotidine | 114 | 34 |
| Allopurinol | Allopurinol | 113 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 113 | 94 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 109 | 27 |
| Pregabalin | Pregabalin | 109 | 23 |
| Valsartan | Valsartan | 103 | 31 |
| Donepezil Hcl | Donepezil Hcl | 98 | 21 |
| Ezetimibe | Ezetimibe | 97 | 27 |
| Nifedipine Er | Nifedipine | 97 | 29 |
| Eliquis | Apixaban | 93 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 24 |
| Warfarin Sodium | Warfarin Sodium | 83 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 19 |
| Montelukast Sodium | Montelukast Sodium | 75 | 27 |
| Finasteride | Finasteride | 74 | 22 |
| Sertraline Hcl | Sertraline Hcl | 74 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 23 |
| Labetalol Hcl | Labetalol Hcl | 71 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 26 |
| Spironolactone | Spironolactone | 69 | 21 |
| Memantine Hcl | Memantine Hcl | 65 | 13 |
| Propranolol Hcl | Propranolol Hcl | 65 | 17 |
| Doxepin Hcl | Doxepin Hcl | 64 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 64 | 14 |
| Eszopiclone | Eszopiclone | 63 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 21 |
| Glimepiride | Glimepiride | 60 | 14 |
| Synthroid | Levothyroxine Sodium | 60 | suppressed |
| Lovastatin | Lovastatin | 58 | 13 |
| Farxiga | Dapagliflozin Propanediol | 57 | 19 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 12 |
| Buspirone Hcl | Buspirone Hcl | 56 | 14 |
| Meloxicam | Meloxicam | 56 | 17 |
| Xarelto | Rivaroxaban | 55 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 15 |
| Jardiance | Empagliflozin | 54 | 19 |
| Prednisone | Prednisone | 54 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 46 |
| Alendronate Sodium | Alendronate Sodium | 50 | 16 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 50 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 18 |
| Azithromycin | Azithromycin | 47 | 39 |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | suppressed |
| Atenolol | Atenolol | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 12 |
| Novolog Flexpen | Insulin Aspart | 38 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 11 |
| Temazepam | Temazepam | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Cefdinir | Cefdinir | 35 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Colchicine | Colchicine | 32 | 14 |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Nystatin | Nystatin | 32 | 22 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 14 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 19 |
| Baclofen | Baclofen | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 25 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 23 |
| Primidone | Primidone | 28 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 21 |
| Metronidazole | Metronidazole | 24 | 23 |
| Ondansetron Odt | Ondansetron | 24 | 19 |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Nabumetone | Nabumetone | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Rybelsus | Semaglutide | 17 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,365.77 · 101 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, CONTRAVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GARDASIL 9, GEMTESA, INCEPTIV, INSPIRE, JARDIANCE, KISUNLA, KRYSTEXXA, Kerendia, Korlym, Leqembi, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ohtuvayre, Ozempic, REPATHA, REXULTI, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, Veozah, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error